DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

ABSTRACT:

Purpose

The current classification systems of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully reflect the molecular heterogeneity of the disease. Molecular characterization may predict clinical outcome and help stratify patients for targeted therapies. Epigenetic therapy using decitabine, a DNA hypomethylating agent, is clinically effective for the treatment of MDS. Therefore, we investigated the association between DNA methylation and clinical outcome in MDS.

Patients and methods

We screened 24 patients with MDS for promoter CpG island methylation of 24 genes and identified aberrant hypermethylation at 10 genes. We then performed quantitative methylation analyses by bisulfite pyrosequencing of the identified genes

SUBMITTER: Shen L 

PROVIDER: S-EPMC2815995 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature